Overview

  • Product nameAnti-Cdc25C antibody
    See all Cdc25C primary antibodies
  • Description
    Mouse monoclonal to Cdc25C
  • Tested applicationsSuitable for: ELISA, IHC-P, WBmore details
  • Species reactivity
    Reacts with: Human
    Predicted to work with: Chimpanzee, Rhesus monkey
  • Immunogen

    Recombinant fragment with tag: FRSNQRKMLN LLLERDTSFT VCPDVPRTPV GKFLGDSANL SILSGGTPKC CLDLSNLSSG EITATQLTTS ADLDETGHLD SSGLQEVHLA GMNHDQHLMK CSPAQLLCST, corresponding to amino acids 21-130 of Human Cdc25C

  • Positive control
    • HeLa cell lysate. Human salivary gland tissue.

Properties

Associated products

Applications

Our Abpromise guarantee covers the use of ab66235 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use at an assay dependent concentration.

The detection limit for recombinant tagged Cdc25C is approximately 0.1ng/ml as a capture antibody.

IHC-P Use a concentration of 6 µg/ml.
WB Use a concentration of 1 - 5 µg/ml. Detects a band of approximately 53 kDa (predicted molecular weight: 53 kDa).

Target

  • FunctionFunctions as a dosage-dependent inducer in mitotic control. It is a tyrosine protein phosphatase required for progression of the cell cycle. It directly dephosphorylates CDK1 and activate its kinase activity.
  • Sequence similaritiesBelongs to the MPI phosphatase family.
    Contains 1 rhodanese domain.
  • Developmental stageExpressed predominantly in G2 phase.
  • Post-translational
    modifications
    Phosphorylated by CHK1 on Ser-216. This phosphorylation creates a binding site for 14-3-3 protein and inhibits the phosphatase. Phosphorylated by PLK4.
  • Cellular localizationNucleus.
  • Information by UniProt
  • Database links
  • Alternative names
    • CDC 25 antibody
    • Cdc 25C antibody
    • CDC25 antibody
    • CDC25C antibody
    • Cell division cycle 25 homolog C antibody
    • Cell division cycle 25C antibody
    • Cell division cycle 25C protein antibody
    • Dual specificity phosphatase Cdc25C antibody
    • M phase inducer phosphatase 3 antibody
    • M-phase inducer phosphatase 3 antibody
    • Mitosis inducer CDC25 antibody
    • MPIP3 antibody
    • MPIP3_HUMAN antibody
    • Phosphotyrosine phosphatase antibody
    • PPP1R60 antibody
    • protein phosphatase 1, regulatory subunit 60 antibody
    see all

Anti-Cdc25C antibody images



  • Predicted band size : 53 kDa

    Lane 1: Wild-type HAP1 cell lysate (20 µg)
    Lane 2: Cdc25C knockout HAP1 cell lysate (20 µg)
    Lane 3: HeLa cell lysate (20 µg)
    Lanes 1 - 3: Merged signal (red and green). Green - ab66235 observed at 58 kDa. Red - loading control, ab181602, observed at 37 kDa.
    ab66235 was shown to recognize Cdc25C when Cdc25C knockout samples were used, along with additional cross-reactive bands. Wild-type and Cdc25C knockout samples were subjected to SDS-PAGE. ab66235 and ab181602 (loading control to GAPDH) were diluted 1 μg/mL and 1/10 000 respectively and incubated overnight at 4°C. Blots were developed with goat anti-rabbit IgG (H + L) and goat anti-mouse IgG (H + L) secondary antibodies at 1/10 000 dilution for 1 h at room temperature before imaging.

  • ab66235, at 6µg/ml, staining Cdc25C in human salivary gland by Immunohistochemistry using formalin-fixed, paraffin-embedded tissue.
  • Anti-Cdc25C antibody (ab66235) at 1 µg/ml + HeLa cell lysate at 50 µg

    Secondary
    Goat Anti-Mouse IgG (H&L)-HRP at 1/2500 dilution

    Predicted band size : 53 kDa
    Observed band size : 53 kDa
    Additional bands at : 36 kDa. We are unsure as to the identity of these extra bands.

References for Anti-Cdc25C antibody (ab66235)

ab66235 has not yet been referenced specifically in any publications.

Product Wall

There are currently no Abreviews or Questions for ab66235.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"